A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
← catalyst calendarNCT04817007 · readout in 742 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
216estimated
Sites
49
Countries
Australia, France, Germany +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-22 | actual | When the study began enrolling |
| Primary completion | 2028-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelofibrosis
Interventions
- Drug: BMS-986158
- Drug: Ruxolitinib — also filed as Jakafi®
- Drug: Fedratinib
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs)
measured Up to 52 months
Incidence of serious adverse events (SAEs)
measured Up to 52 months
Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
measured Up to 26 months
Incidence of AEs leading to discontinuation
measured Up to 52 months
Incidence of death
measured Up to 52 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed